Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elafibranor in Primary Biliary Cholangitis (PBC) with Cirrhosis
NCT06016842Phase 3Recruiting
- Sponsor
- Ipsen
- Start
- Aug 2023
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 28
01
Overview
A Phase 3 trial of elafibranor in primary biliary cholangitis (PBC), sponsored by Ipsen. Started Aug 2023; status: recruiting.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT06016842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016842.